Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 7,384 shares at $141.19 ($1.0M) on 2016-02-05, disclosed to the SEC on 2016-02-08.
Open-market sale of $1.0M ALXN by EVP & Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $140.47 | 1,043 | $147K | 14.2% |
| 2 | $140.47 | 1,043 | $147K | 14.2% |
| 3 | $141.19 | 400 | $56K | 5.5% |
| 4 | $142.11 | 100 | $14K | 1.4% |
| 5 | $143.53 | 100 | $14K | 1.4% |
| 6 | $144.40 | 362 |
| $52K |
| 5.1% |
| 7 | $144.40 | 362 | $52K | 5.1% |
| 8 | $145.54 | 100 | $15K | 1.4% |
| 9 | $138.02 | 1,908 | $263K | 25.5% |
| 10 | $138.02 | 1,908 | $263K | 25.5% |
| 11 | $140.32 | 58 | $8K | 0.8% |
| Total | $139.76 avg | 7,384 | $1.0M | 100% |
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |